Biomarkers of Hypoxic-Ischemic Encephalopathy in Newborns | ||
| Journal of Integrated Maternal and Pediatric Care | ||
| Article 5, Volume 3, Issue 1, March 2020, Pages 28-36 PDF (385.47 K) | ||
| Document Type: Scientific Review | ||
| DOI: 10.18502/wjpn.v3i1.5063 | ||
| Authors | ||
| Mahmood Noorishadkam1; Shekoofeh Savabieh* 1; Mohammad Emad Sharifi2 | ||
| 1Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | ||
| 2Dentistry Student, School of Dental Medicine, Tehran University of Medical Sciences, Tehran, Iran | ||
| Abstract | ||
| Biomarkers are particles that are released from target organs during tissue hypoxia injury. Recognizing biomarkers released from the damaged brain helps physicians determine the extent of tissue damage and the use of protective techniques in clinical treatment. Previous studies revealed that biomarkers such as brain-specific proteins (neuron-specific enolase (NSE), S100B, ubiquitincarboxy-terminal hydrolase-L1, total Tau) and cytokines, including IL-6, IL-1β, IL-10, IL-13, interferon-gamma, TNF alpha and brain-derived neurotrophic factor are useful in diagnosing hypoxic-ischemic encephalopathy (HIE) and predicting nerve growth outcomes. However, optimal sensitivity and specificity of these biomarkers have not been achieved, which has limited their clinical application. This review focuses on biomarkers such as lactate, LDH, NRBC, NSE, S100B, GFAP, CPK-BB, IL-6, NPBI, UCHL-1. More sensitive and accurate instruments such as brain imaging (such as brain MRI), brain function (such as NIRS, aEEG), and long-term neuroassay should be used in the future to confirm biomarkers of neonatal brain damage. | ||
| Keywords | ||
| Hypothermia; Biomarker; Encephalopathy; Brain | ||
| References | ||
|
| ||
|
Statistics Article View: 529 PDF Download: 260 |
||